JP5276005B2 - ピリジノン化合物 - Google Patents
ピリジノン化合物 Download PDFInfo
- Publication number
- JP5276005B2 JP5276005B2 JP2009536476A JP2009536476A JP5276005B2 JP 5276005 B2 JP5276005 B2 JP 5276005B2 JP 2009536476 A JP2009536476 A JP 2009536476A JP 2009536476 A JP2009536476 A JP 2009536476A JP 5276005 B2 JP5276005 B2 JP 5276005B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitors
- kinase
- agents
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000005299 pyridinones Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 51
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- 201000011510 cancer Diseases 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 25
- 239000003112 inhibitor Substances 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 21
- -1 alkyl nitrosourea Chemical compound 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000004913 activation Effects 0.000 claims description 13
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 229940043355 kinase inhibitor Drugs 0.000 claims description 11
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 11
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 208000005017 glioblastoma Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 6
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 102000004584 Somatomedin Receptors Human genes 0.000 claims description 6
- 108010017622 Somatomedin Receptors Proteins 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 230000000638 stimulation Effects 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 206010003571 Astrocytoma Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 230000004544 DNA amplification Effects 0.000 claims description 5
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 5
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 5
- 206010027406 Mesothelioma Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 201000010175 gallbladder cancer Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 201000008968 osteosarcoma Diseases 0.000 claims description 5
- 239000000186 progesterone Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 230000022131 cell cycle Effects 0.000 claims description 4
- 239000002254 cytotoxic agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 229940011871 estrogen Drugs 0.000 claims description 4
- 239000000262 estrogen Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 claims description 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 3
- 101100066427 Homo sapiens FCGR1A gene Proteins 0.000 claims description 3
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 102000029749 Microtubule Human genes 0.000 claims description 3
- 108091022875 Microtubule Proteins 0.000 claims description 3
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims description 3
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 3
- 229940123237 Taxane Drugs 0.000 claims description 3
- 239000002487 adenosine deaminase inhibitor Substances 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000003098 androgen Substances 0.000 claims description 3
- 229940030486 androgens Drugs 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 3
- 230000002280 anti-androgenic effect Effects 0.000 claims description 3
- 239000000051 antiandrogen Substances 0.000 claims description 3
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 3
- 239000003886 aromatase inhibitor Substances 0.000 claims description 3
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 3
- 239000003719 aurora kinase inhibitor Substances 0.000 claims description 3
- 230000000368 destabilizing effect Effects 0.000 claims description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 3
- 229940121647 egfr inhibitor Drugs 0.000 claims description 3
- 229930013356 epothilone Natural products 0.000 claims description 3
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims description 3
- 239000004052 folic acid antagonist Substances 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000000367 immunologic factor Substances 0.000 claims description 3
- 102000006495 integrins Human genes 0.000 claims description 3
- 108010044426 integrins Proteins 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims description 3
- 210000004688 microtubule Anatomy 0.000 claims description 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 3
- 229940124303 multikinase inhibitor Drugs 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 239000000583 progesterone congener Substances 0.000 claims description 3
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims description 3
- 150000003212 purines Chemical class 0.000 claims description 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 102000009076 src-Family Kinases Human genes 0.000 claims description 3
- 108010087686 src-Family Kinases Proteins 0.000 claims description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 3
- 239000003558 transferase inhibitor Substances 0.000 claims description 3
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 4
- 229940080778 Adenosine deaminase inhibitor Drugs 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 241000863480 Vinca Species 0.000 claims 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 239000000328 estrogen antagonist Substances 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 2
- 229960004961 mechlorethamine Drugs 0.000 claims 2
- 230000002297 mitogenic effect Effects 0.000 claims 2
- 229960003387 progesterone Drugs 0.000 claims 2
- AYNNSCRYTDRFCP-UHFFFAOYSA-N triazene Chemical compound NN=N AYNNSCRYTDRFCP-UHFFFAOYSA-N 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 239000005434 MCC/mannitol excipient Substances 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 93
- 239000000203 mixture Substances 0.000 description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000007787 solid Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 30
- 235000002639 sodium chloride Nutrition 0.000 description 21
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 20
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000003814 drug Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 229940125904 compound 1 Drugs 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 108700020796 Oncogene Proteins 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- QEYCCTFCRIPTDO-UHFFFAOYSA-N 3,4-dichloropyridine-2-carboxamide Chemical compound NC(=O)C1=NC=CC(Cl)=C1Cl QEYCCTFCRIPTDO-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- VNBRGSXVFBYQNN-UHFFFAOYSA-N N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-3-pyridinecarboxamide Chemical group O=C1C(C(=O)NC=2C=C(F)C(OC=3C(=C(N)N=CC=3)Cl)=CC=2)=C(OCC)C=CN1C1=CC=C(F)C=C1 VNBRGSXVFBYQNN-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- ZMPYQKNNUHPTLT-UHFFFAOYSA-N 3,4-dichloropyridine Chemical compound ClC1=CC=NC=C1Cl ZMPYQKNNUHPTLT-UHFFFAOYSA-N 0.000 description 3
- AFZMKBLOQNTBOT-UHFFFAOYSA-N 3,4-dichloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC(Cl)=C1Cl AFZMKBLOQNTBOT-UHFFFAOYSA-N 0.000 description 3
- ZVUCRWKAALPUNZ-UHFFFAOYSA-N 4-(4-amino-2-fluorophenoxy)-3-chloropyridine-2-carboxamide Chemical compound NC(=O)C1=NC=CC(OC=2C(=CC(N)=CC=2)F)=C1Cl ZVUCRWKAALPUNZ-UHFFFAOYSA-N 0.000 description 3
- GNBKAOHTTIVAMT-UHFFFAOYSA-N 4-iodo-2-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC=CC(I)=C1C=O GNBKAOHTTIVAMT-UHFFFAOYSA-N 0.000 description 3
- WVKLERKKJXUPIK-UHFFFAOYSA-N 7-phenylmethoxy-4-(trifluoromethyl)chromen-2-one Chemical compound C1=CC=2C(C(F)(F)F)=CC(=O)OC=2C=C1OCC1=CC=CC=C1 WVKLERKKJXUPIK-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 102000003849 Cytochrome P450 Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 3
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 230000009087 cell motility Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- ZXNZHVDQMZJUKH-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound O=C1C(C(=O)N)=CC=CN1C1=CC=C(F)C=C1 ZXNZHVDQMZJUKH-UHFFFAOYSA-N 0.000 description 2
- CGDDRASYDFHWHN-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-iodo-2-oxopyridine-3-carboxylic acid Chemical compound O=C1C(C(=O)O)=C(I)C=CN1C1=CC=C(F)C=C1 CGDDRASYDFHWHN-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- WCDCAXVNBOLWNO-UHFFFAOYSA-N 2-fluoro-3-iodopyridine Chemical compound FC1=NC=CC=C1I WCDCAXVNBOLWNO-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 2
- MSJYKVLQESELLY-UHFFFAOYSA-N 4-iodo-2-oxo-1h-pyridine-3-carbaldehyde Chemical compound OC1=NC=CC(I)=C1C=O MSJYKVLQESELLY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HKLZIJGDTNSHBI-UHFFFAOYSA-N C[SiH](C)C.N=C=O Chemical compound C[SiH](C)C.N=C=O HKLZIJGDTNSHBI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000002137 anti-vascular effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- RWWVKYGSTBVGSN-UHFFFAOYSA-N n-[4-(2-carbamoyl-3-chloropyridin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound O=C1C(C(=O)NC=2C=C(F)C(OC=3C(=C(C(N)=O)N=CC=3)Cl)=CC=2)=C(OCC)C=CN1C1=CC=C(F)C=C1 RWWVKYGSTBVGSN-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- JTRIUPVSQUCCHH-UHFFFAOYSA-N $l^{1}-oxidanylsulfinylmethane Chemical compound C[S](=O)=O JTRIUPVSQUCCHH-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UCLKLGIYGBLTSM-UHFFFAOYSA-N 1,2,3,4-tetrachloro-5-(2,5-dichlorophenyl)benzene Chemical compound ClC1=CC=C(Cl)C(C=2C(=C(Cl)C(Cl)=C(Cl)C=2)Cl)=C1 UCLKLGIYGBLTSM-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- SMQAYADVUGGRBW-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-iodo-2-oxopyridine-3-carbaldehyde Chemical compound C1=CC(F)=CC=C1N1C(=O)C(C=O)=C(I)C=C1 SMQAYADVUGGRBW-UHFFFAOYSA-N 0.000 description 1
- BDHOFSHQQZVPPL-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-iodo-2-oxopyridine-3-carbaldehyde;1-(4-fluorophenyl)-4-iodo-2-oxopyridine-3-carboxylic acid Chemical compound C1=CC(F)=CC=C1N1C(=O)C(C=O)=C(I)C=C1.O=C1C(C(=O)O)=C(I)C=CN1C1=CC=C(F)C=C1 BDHOFSHQQZVPPL-UHFFFAOYSA-N 0.000 description 1
- DBAIQQSWGZJOQS-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-iodo-2-oxopyridine-3-carbaldehyde;4-iodo-2-oxo-1h-pyridine-3-carbaldehyde Chemical compound IC=1C=CNC(=O)C=1C=O.C1=CC(F)=CC=C1N1C(=O)C(C=O)=C(I)C=C1 DBAIQQSWGZJOQS-UHFFFAOYSA-N 0.000 description 1
- CAJXQVJSWADTQZ-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-iodo-2-oxopyridine-3-carboxamide Chemical compound FC1=CC=C(C=C1)N1C(C(=C(C=C1)I)C(=O)N)=O CAJXQVJSWADTQZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KKSGOOJPXBUJIA-UHFFFAOYSA-N 3-[2-(diethylamino)ethyl]-7-hydroxy-4-methylchromen-2-one Chemical compound C1=C(O)C=C2OC(=O)C(CCN(CC)CC)=C(C)C2=C1 KKSGOOJPXBUJIA-UHFFFAOYSA-N 0.000 description 1
- MXJQJURZHQZLNN-UHFFFAOYSA-N 4-amino-2-fluorophenol Chemical compound NC1=CC=C(O)C(F)=C1 MXJQJURZHQZLNN-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- YAFGHMIAFYQSCF-UHFFFAOYSA-N 7-ethoxy-2-oxochromene-3-carbonitrile Chemical compound C1=C(C#N)C(=O)OC2=CC(OCC)=CC=C21 YAFGHMIAFYQSCF-UHFFFAOYSA-N 0.000 description 1
- IJQYTHQDUDCJEQ-UHFFFAOYSA-N 7-hydroxy-2-oxochromene-3-carbonitrile Chemical group C1=C(C#N)C(=O)OC2=CC(O)=CC=C21 IJQYTHQDUDCJEQ-UHFFFAOYSA-N 0.000 description 1
- CCKWMCUOHJAVOL-UHFFFAOYSA-N 7-hydroxy-4-(trifluoromethyl)chromen-2-one Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(O)=CC=C21 CCKWMCUOHJAVOL-UHFFFAOYSA-N 0.000 description 1
- HAZHUELNIGDYQH-UHFFFAOYSA-N 7-methoxy-4-(trifluoromethyl)chromen-2-one Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(OC)=CC=C21 HAZHUELNIGDYQH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GDXXYJRQFQZYNL-UHFFFAOYSA-N 9h-fluoren-1-ylmethyl carbamate Chemical compound C1C2=CC=CC=C2C2=C1C(COC(=O)N)=CC=C2 GDXXYJRQFQZYNL-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- AVMJURIHSACQED-UHFFFAOYSA-N CC1=NC=CC(=C1Cl)OC2=C(C=C(C=C2)NC(=O)C3=C(C=CN(C3=O)C4=CC=C(C=C4)F)Cl)F Chemical compound CC1=NC=CC(=C1Cl)OC2=C(C=C(C=C2)NC(=O)C3=C(C=CN(C3=O)C4=CC=C(C=C4)F)Cl)F AVMJURIHSACQED-UHFFFAOYSA-N 0.000 description 1
- 101100447914 Caenorhabditis elegans gab-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100298362 Homo sapiens PPIG gene Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 101150105382 MET gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000004422 Phospholipase C gamma Human genes 0.000 description 1
- 108010056751 Phospholipase C gamma Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-N calcium;phosphoric acid Chemical compound [Ca+2].OP(O)(O)=O.OP(O)(O)=O YYRMJZQKEFZXMX-UHFFFAOYSA-N 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032341 cell morphogenesis Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- JSKZWIGBDHYSGI-UCSXVCBISA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-[1-[2-(3,4-dihydroxybenzoyl)hydrazinyl]-2-methyl-1-oxopropan-2-yl]oxyiminoacetyl]amino]-3-[(2-carboxylato-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2. Chemical compound [Na+].[Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)CSC1=CC(=NC2=NC(=NN21)C([O-])=O)C)C([O-])=O)C(=O)C(\C=1N=C(N)SC=1)=N\OC(C)(C)C(=O)NNC(=O)C1=CC=C(O)C(O)=C1 JSKZWIGBDHYSGI-UCSXVCBISA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000056262 human PPIG Human genes 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- SFLFBNIUTUIIHM-UHFFFAOYSA-N n-[4-(2-carbamoyl-3-chloropyridin-4-yl)oxy-3-fluorophenyl]-1-(4-fluorophenyl)-4-iodo-2-oxopyridine-3-carboxamide Chemical compound NC(=O)C1=NC=CC(OC=2C(=CC(NC(=O)C=3C(N(C=4C=CC(F)=CC=4)C=CC=3I)=O)=CC=2)F)=C1Cl SFLFBNIUTUIIHM-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 231100000822 oral exposure Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000009120 phenotypic response Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- PANBYUAFMMOFOV-UHFFFAOYSA-N sodium;sulfuric acid Chemical compound [Na].OS(O)(=O)=O PANBYUAFMMOFOV-UHFFFAOYSA-N 0.000 description 1
- 239000011973 solid acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000002426 superphosphate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Description
以下の記載は、本発明を説明するために用いる様々な用語の定義である。これらの定義は、個々にまたは大きな基の一部として、(特定の例において他に制限されない限り)本明細書を通じて用いられる用語に適用される。
またはその塩に関する。本発明の化合物は、既知のMetキナーゼ阻害剤を超える、力価増大および特定のCYP450アイソザイムに対する抑制低下の理由から、特に癌の治療に有用であることを見いだした。
Marzi, E. et al. (Eur. J. Org. Chem. 2001, 1371-1376)による前述の通り、2,2,6,6-テトラメチルピペリジン(8.84 mL, 52 mmol, Aldrich)/50 mLのエーテルを、0℃で、n-BuLi(33 mL, 52 mmol, Aldrich, 1.6 Mヘキサン)でチャージした。0℃で30分間撹拌後、該溶液を-78℃まで冷却し、3,4-ジクロロピリジン(7.0 g, 47 mmol, Matrix)/5 mLエーテルの溶液でチャージした。-78℃で2時間撹拌後、カニューレを介して二酸化炭素(ドライアイス)を該反応混合液にバブルすると、該溶液は不均一となった。二酸化炭素を該反応液に-78℃で10分間バブルした後、該冷却槽を取り外し、該反応混合液を、CO2バブルをしながら室温まで温めた。該反応液を飽和塩化アンモニウム水溶液(〜50 mL)でクエンチし、大気圧下、室温で5分間撹拌した。該反応混合液を水(〜150 mL)で希釈し、酢酸エチル(2×75 mL)で抽出していずれの残留出発物質をも除去した。該水層を1NのHCl水溶液でpH 1〜2に酸性化し、酢酸エチル(2×100 mL)で抽出した。該有機相を無水硫酸マグネシウムで乾燥させ、減圧濃縮して、3,4-ジクロロピコリン酸(3.5 g, 39%)を黄色固形物として得た。1H NMR (DMSO-d6) δ8.53 (d, 1H, J=5.2 Hz), 7.90 (d, 1H, J=5.2 Hz); MS(ESI+) m/z 192.08 (M + H)+.
3,4-ジクロロピコリン酸(3.5 g, 18 mmol)/過剰な塩化チオニル(10 mL, Aldrich ReagentPlus 99.5%)の混合液を80℃で1時間撹拌した。室温まで冷却した後、該反応液を減圧濃縮して過剰な塩化チオニルを除去し、次いで、エーテル(50 mL)に懸濁した。該エーテル性酸クロリド溶液を、水酸化アンモニウム(50 mL)に0℃で添加した。該生成物を減圧濾過により集め、水洗した後、エーテルでトリチュレートして、3,4-ジクロロピコリンアミド(2.6 g, 76%)をベージュ色(biege)固形物として得た。1H NMR (DMSO-d6) δ8.50 (d, 1H, J=5.2 Hz), 8.12 (br s, 1H), 7.83 (d, 1H, J=5.2 Hz), 7.82 (br s, 1H); MS(ESI+) m/z 191.10 (M + H)+.
2,2,6,6-テトラメチルピペリジン(31.1 g, 0.22 mol)/ジエチルエーテル(400 mL)溶液に、0℃でn-BuLi/ヘキサン(1.6 M, 138.0 mL, 0.22 mol)を、シリンジを介して15分かけて添加した。得られた溶液を、0℃で0.5時間および-78℃で0.5時間撹拌した。ついで、該混合液に、3,4-ジクロロピリジン(29.6 g, 0.20 mol)/ジエチルエーテル(20 mL)溶液を、シリンジを介して15分かけてゆっくりと添加した。得られた混合液を-78℃で2時間撹拌した後、イソシアナートトリメチルシラン (85 %純度, 40.0 mL, 0.30 mol)を添加した。イソシアナートトリメチルシランの供給源はTCIである。該添加後、冷却槽を取り外し、該反応混合液を室温まで1時間かけて温めた。該反応混合液を、酢酸(40 g, 0.67 mol)および200 mLの水でクエンチした。該混合液を終夜撹拌し、生じた白色固形物を濾過により集め、水洗した。該ろ液を酢酸エチル(3×300 mL)で抽出した。前に集めた該固形物を、合わせた有機層中に溶解し、得られた溶液を食塩水(2×200 mL)で洗浄し、MgSO4で乾燥させ、減圧濃縮した。該残渣を200 mLのジエチルエーテルに懸濁し、超音波処理した。該残留固形物を濾過により集め、最少量のジエチルエーテルで洗浄して、3,4-ジクロロピコリンアミド(14.8 g, 39%)を得た。
4-アミノ-2-フルオロフェノール(9.3 g, 73 mmol, 3B Medical Systems, 3B3290)/DMF(100 mL)溶液に、カリウムtert-ブトキシド(8.8 g, 79 mmol)を添加した。室温で30分間撹拌した後、3,4-ジクロロピコリンアミド(10 g, 52 mmol)を添加した。該反応混合液を50℃で2.5時間撹拌した。該反応液を室温まで冷却した後、該混合液を400 mLの酢酸エチルで希釈し、飽和炭酸水素ナトリウム水溶液(400 mL)で洗浄した。該水層を300 mL酢酸エチルで逆抽出した(back-extracted)。有機相を合わせて、10%塩化リチウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥させて、減圧濃縮した。得られた茶色固形物を酢酸エチルに懸濁し、濾過して、エーテルで洗浄して、黄褐色固形物として生成物を得た(7.4 g)。該ろ液を減圧濃縮した後、シリカゲルでのフラッシュクロマトグラフィー(2%メタノール/酢酸エチル)により精製した。得られた茶色固形物をエーテルでトリチュレートして、さらに4.3 gの4-(4-アミノ-2-フルオロフェノキシ)-3-クロロピコリンアミド(79%合わせた収率)を淡黄褐色固形物として得た。1H NMR (CD3OD) δ8.29 (d, 1H, J=5.6 Hz), 7.00 (t, 1H, J=8.8 Hz), 6.79 (d, 1H, J=5.6 Hz), 6.63-6.55 (m, 2H); MS(ESI+) m/z 282.21 (M + H)+.
ジイソプロピルアミン(260 g, 2.57 mol)/無水THF(6.5 L)溶液に、N2のブランケット下、-30℃から-40℃で、n-BuLi (156 g, 2.45 mol)を、カニューレを介して滴下した。得られた溶液を0℃まで温め、該温度で35分間撹拌した。次いで、該溶液を-78℃に冷却し、2-フルオロピリジン(250 g, 2.57 mol, Alfa)を滴下した。該反応混合液を-78℃で2時間撹拌した。その後、該混合液をヨウ素(654 g, 2.57 mol)/無水THF(1.96 L)溶液に、-20℃、N2下でカニューレを介して添加した。該反応が完了した後、該混合液を氷水でクエンチし、EtOAcで抽出した。該有機層をチオ硫酸ナトリウムで洗浄し、続いて水および食塩水で洗浄した。次いで、該有機物を乾燥させ(Na2SO4)、減圧濃縮すると2-フルオロ-3-ヨードピリジン(450 g, 78%)が固形物として得られ、それは後続のステップで用いるのに十分純粋であった。
ジイソプロピルアミン(345 mL, 249 g, 2.46 mol)/無水THF(5 L)溶液に、N2のブランケット下、-8から-10℃でn-BuLi(880 mL, 158 g, 2.46 mol)を、カニューレを介して滴下した。該混合液を-10℃で30分間撹拌し、-78℃まで冷却して、2-フルオロ-3-ヨードピリジン(500 g, 2.24 mol)/乾燥THF(2 L)溶液で滴下処理した。添加後、該反応混合液を-60℃まで温め、該温度を2時間維持した。次いで、該混合液を-78℃に冷却し、ギ酸エチル(183 g, 2.47 mol)で滴下処理した後、ナトリウムメトキシド(149 g, 2.75 mol)/MeOH(1.5 L)で処理し、周囲温度まで昇温させた。該反応混合液を氷水でクエンチし、EtOAcで抽出した。該層を分離し、該有機相を水および食塩水で洗浄し、乾燥させ(Na2SO4)て減圧濃縮した。該残渣を、シリカゲルでのフラッシュクロマトグラフィーにより精製して、4-ヨード-2-メトキシニコチンアルデヒド(380 g, 64%)を固形物として得た。
別法として、4-ヨード-2-メトキシニコチンアルデヒドを、米国特許第5,491,237号(WO 95/29917)に記載の方法に従って製造することができる。
4-ヨード-2-メトキシニコチンアルデヒド(25 g, 95 mmol)およびヨウ化ナトリウム(31.0 g, 285 mmol, Aldrich)を、500 mLのアセトニトリル中で一緒に撹拌した。該溶液に、クロロトリメチルシラン(36.0 mL, 285 mmol, Aldrich >99%)を、15分かけて滴下した。該反応混合液を室温で2時間撹拌した後、減圧濃縮した。該生成物を、酢酸エチル、水、および飽和炭酸水素ナトリウム水溶液に懸濁し、次いで濾過して、暗褐色固形物を得た。該固形物をアセトニトリルでトリチュレートして、4-ヨード-2-オキソ-1,2-ジヒドロピリジン-3-カルバルデヒド(21.3 g, 90%)を黄色固形物として得た(互変異性体の混合物)。MS(ESI+) m/z 250.04 (M + H)+.
4-ヨード-2-オキソ-1,2-ジヒドロピリジン-3-カルバルデヒド(16.0 g, 64.3 mmol)、4-フルオロフェニルボロン酸(26.8 g, 193 mmol, Aldrich)、酢酸銅(II)(23.4 g, 129 mmol, Aldrich)、およびミリスチン酸(58.7 g, 257 mmol, Aldrich)を、800 mLのトルエン中で一緒に撹拌した。該溶液に、2,6-ルチジン(60 mL, 514 mmol, Aldrich)を添加し、該反応液を1日間激しく撹拌した。さらなる5 gの4-フルオロフェニルボロン酸を添加し、該反応液を、さらに3日間激しく撹拌した。該反応混合液を濃縮して、次いで10%メタノール/酢酸エチルに懸濁した。セライト(登録商標)を添加し、該混合液を5分間撹拌した。次に、該混合液をセライト(登録商標)プラグを通して濾過し、濃縮して、酢酸エチルおよび水に懸濁した。該混合液を、セライト(登録商標)を通して再度濾過して、酢酸エチルで十分に洗浄しながら、析出したさらなる銅を除去した。該ろ液を1N HCl水溶液で洗浄し、硫酸ナトリウムで乾燥させ、濾過し、減圧濃縮した。得られた固形物を酢酸エチルでトリチュレートして、9.25 g(42 %)の1-(4-フルオロフェニル)-4-ヨード-2-オキソ-1,2-ジヒドロピリジン-3-カルバルデヒドを黄色固形物として得た。該ろ液を減圧濃縮し、該残留固形物を酢酸エチルで再度トリチュレートして、さらなる5.75 g(68 %総収率)の目的物を黄色固形物として得た。1H NMR (DMSO-d6) δ9.57 (s, 1H), 7.68 (d, 1H, J=7.2 Hz), 7.58-7.54 (m, 2H), 7.40 (t, 2H, J=8.8 Hz), 7.02 (d, 1H, J=7.2 Hz); MS(ESI+) m/z 344.13 (M + H)+.
1-(4-フルオロフェニル)-4-ヨード-2-オキソ-1,2-ジヒドロピリジン-3-カルバルデヒド (10.0 g, 29.2 mmol)およびリン酸二水素ナトリウム(10.1 g, 73 mmol, Aldrich)を、各35 mLのTHF、tert-ブタノール、および水中において、0℃で激しく撹拌した。2-メチル-2-ブテン(45.2 mL, 2.0 M/THF, Aldrich)を該反応混合液に添加し、続いて亜塩素酸ナトリウム(6.06 g, 67.1 mmol, Aldrich)を添加した。該氷浴を取り外し、該反応混合液を非常に急速に撹拌しながら室温まで昇温させた。数分後、目的物が溶液から析出し始めた。1時間撹拌し続けた後、20 mLの1N HCl水溶液を添加し、さらに5分間撹拌を続けた。目的物をろ取し、次いで水、酢酸エチルおよびエーテルで洗浄した。該ろ液を採集し、該層を分離した。該水層を酢酸エチルで抽出した。有機層を合わせて硫酸マグネシウムで乾燥させ、濾過し、減圧濃縮した。得られた固形物を酢酸エチルに懸濁し、濾過し、酢酸エチルおよびエーテルで洗浄してさらなる目的物を得た。該淡黄色固形物を合わせて、8.22 g(78 %)の1-(4-フルオロフェニル)-4-ヨード-2-オキソ-1,2-ジヒドロピリジン-3-カルボン酸を得た(92 %純度, 8 %出発物質残留)。該物質を最少量の1N NaOH水溶液に溶解した。酢酸エチルを添加し、該混合液を5分間激しく撹拌した。該層を分離し、該水層を酢酸エチルで抽出した。該水層を、濃HClを用いて、撹拌しながらpH 1に酸性化した。溶液から析出した該淡黄色固形物を集め、水、酢酸エチル、ジエチルエーテルで洗浄し、次いで減圧下で乾燥させて、7.33 g(70 %)の1-(4-フルオロフェニル)-4-ヨード-2-オキソ-1,2-ジヒドロピリジン-3-カルボン酸(95.4 %HPLCによる純度)を得た。1H NMR (DMSO-d6)δ13.53 (s, 1H), 7.52-7.49 (m, 3H), 7.38 (t, 2H, J=8.8 Hz), 6.81 (d, 1H, J=7.2 Hz); MS(ESI+) m/z 360.14 (M + H)+.
1-(4-フルオロフェニル)-4-ヨード-2-オキソ-1,2-ジヒドロピリジン-3-カルボン酸 (3.7 g, 10 mmol)/6 mLのトルエンに、塩化チオニル(10 mL, Aldrich ReagentPlus 99.5%)を添加した。室温で2.5時間撹後、該混合液は均質となり、次いで、減圧濃縮した。トルエン(3 mL)を該残渣に添加し、該混合液を減圧濃縮して過剰な塩化チオニルを除去した(2回実施)。その後、該粗酸塩化物を15分間、高真空下で乾燥させた。酸塩化物を乾燥させている間、4-(4-アミノ-2-フルオロフェノキシ)-3-クロロピコリンアミド(2.5 g, 8.9 mmol)をTHF(50 mL)およびDMF(3 mL)に溶解させた。該溶液を0℃に冷却した後、N,N-ジイソプロピルエチルアミン(3.1 mL, 18 mmol, Aldrich 99.5%再蒸留)を添加した。次いで、固体の該酸塩化物を30分かけて添加した。添加完了後、該冷浴を取り外し、該反応混合液を室温で15分間撹拌した後、飽和炭酸水素ナトリウム水溶液(30 mL)でクエンチした。水を添加して(〜30 mL)該塩を溶解させ、該混合液を酢酸エチル(1×100 mL)で抽出した。該有機相を無水硫酸ナトリウムで乾燥させ、減圧濃縮した。該粗精製物を、シリカゲルでのフラッシュクロマトグラフィー(2%メタノール/酢酸エチル)により精製して、4.9 gの目的物を、少量の3-クロロ-4-(4-(4-クロロ-1-(4-フルオロフェニル)-2-オキソ-1,2-ジヒドロピリジン-3-カルボキサミド)-2-フルオロフェノキシ)ピコリンアミドと共にオフホワイト色固形物として得た(89%ヨウ化物基準)。1H NMR (CD3OD) δ8.34 (d, 1H, J=5.6 Hz), 7.92 (dd, 1H, J=12.4, 2.4 Hz), 7.51-7.47 (m, 4H), 7.37-7.29 (m, 3H), 6.99 (d, 1H, J=7.2 Hz), 6.86 (d, 1H, J=5.6 Hz); MS(ESI+) m/z 623.08 (M + H)+.
水素化ナトリウム(1.89 g, 47.2 mmol, 60%分散/鉱油, Aldrich)を、エタノール(77 mL, Aldrich >99.5% 200プルーフ(proof))およびTHF(77 mL)の溶液に、N2下でゆっくりと添加し、得られた混合液を室温で5分間撹拌した。次いで、該ナトリウムエトキシド溶液を、3-クロロ-4-(2-フルオロ-4-(1-(4-フルオロフェニル)-4-ヨード-2-オキソ-1,2-ジヒドロピリジン-3-カルボキサミド)フェノキシ)-ピコリンアミドおよび3-クロロ-4-(4-(4-クロロ-1-(4-フルオロフェニル)-2-オキソ-1,2-ジヒドロピリジン-3-カルボキサミド)-2-フルオロフェノキシ)ピコリンアミド(22.6 g, 〜36.3 mmol)の混合物に添加し、室温で1時間撹拌した。該反応混合液を減圧濃縮した。得られた粗固形物を酢酸エチル、飽和炭酸水素ナトリウム水溶液、および水に懸濁した(沈殿した塩のいずれかを溶解させるように)。該混合液を超音波処理して、残留固形物が濾過できる粉末になるまで撹拌した。該粉末をろ取し、17.2 g(88 %)の目的物を淡黄色固形物として得た。残ったろ液の層を分離した。該水層を酢酸エチルで抽出した。有機層を合わせて無水硫酸ナトリウムで乾燥させ、減圧濃縮した。得られた固形物を酢酸エチルでトリチュレートし、超音波処理し、濾過し、さらなる3.02 gの目的物を薄茶色固形物として得た。1H NMR (CD3OD) δ8.34 (d, 1H, J=5.6 Hz), 7.94 (dd, 1H, J=12.4, 2.4 Hz), 7.80 (d, 1H, J=8 Hz), 7.48-7.46 (m, 3H), 7.31-7.28 (m, 3H), 6.86 (d, 1H, J=5.6 Hz), 6.61 (d, 1H, J=7.2 Hz), 4.34 (q, 2H, J=7.2 Hz), 1.45 (t, 3H, J=7.2 Hz); MS(ESI+) m/z 541.11 (M + H)+.
3-クロロ-4-(4-(4-エトキシ-1-(4-フルオロフェニル)-2-オキソ-1,2-ジヒドロピリジン-3-カルボキサミド)-2-フルオロフェノキシ)ピコリンアミド(1.2 g, 2.1 mmol)/酢酸エチル(16 mL)、アセトニトリル(16 mL)、および水(8 mL)の溶液に、0℃で、ヨードベンゼンジアセテート(820 mg, 2.6 mmol, Aldrich)を添加した。室温で2時間撹拌後、該反応液を濾過して粗精製物を集めた。該固形物をさらなる酢酸エチルで洗浄した。該ろ液を飽和炭酸水素ナトリウム水溶液で洗浄し、該有機相を無水硫酸ナトリウムで乾燥させ、減圧濃縮した。該沈殿物および濾過物を合わせて、シリカゲルでのフラッシュクロマトグラフィー(2%メタノール/クロロホルム)により精製し、表題の化合物を(810 mg, 74%)白色固形物として得た。1H NMR (DMSO-d6) δ10.57 (s, 1H), 7.83-7.79 (m, 2H), 7.67 (d, 1H, J=5.6 Hz), 7.41-7.38 (m, 3H), 7.36-7.22 (m, 3H), 6.44 (d, 1H, J=7.6 Hz), 6.36 (br s, 2H), 5.86 (d, 1H, J=6.0 Hz), 4.18 (q, 2H, J=7.2 Hz), 1.23 (t, 3H, J=7.2 Hz); MS(ESI+) m/z 513.09 (M + H)+.
本発明の化合物の薬理学的特性は、多くの薬理学的アッセイにより確認することができる。以下に例示の薬理学的アッセイを、本発明の化合物および/またはそれらの塩で実施した。
Metキナーゼアッセイに用いるインキュベーション混合物は、バキュロウイルス発現GST-Metキナーゼ、合成基質ポリGlu:Tyr(4:1)、ATP、ATP-γ-33P、およびMn++、DTT、BSAおよびトリスを含むバッファーを含有する。反応物を30℃で60分間インキュベートし、冷トリクロロ酢酸(TCA)の添加により停止して最終濃度を8%とする。Filtermate汎用ハーベスター(Packard Instrument Co., Meriden, CT)を用いて、TCA沈殿物をGF/Cユニフィルタープレート(Packard Instrument Co., Meriden, CT)に集め、そしてTopCount 96/384-ウェルシンチレーションカウンター(Packard Instrument Co., Meriden, CT)を用いて、該フィルターを定量する。用量反応曲線を作製して、キナーゼ活性50%を阻害するのに必要とされる濃度(IC_50)を求める。化合物を10 mMでジメチルスルホキシド(DMSO)に溶解し、10種の濃度で、それぞれ二つ組で評価する。該アッセイにおいて、DMSOの最終濃度は1.7%である。IC_50値は非線形回帰により導かれる。
N-(4-(2-アミノ-3-クロロピリジン-4-イルオキシ)-3-フルオロフェニル)-4-エトキシ-1-(4-フルオロフェニル)-2-オキソ-1,2-ジヒドロピリジン-3-カルボキサミド(化合物1)の、GTL-16胃腫瘍異種移植片およびU87神経膠芽腫腫瘍異種移植片に対するin vivo有効性について評価した。図1に示すように、6.25 mg/kgから50 mg/kgの範囲の複数の用量レベルで、化合物1は、GTL-16ヒト胃癌モデルに対する少なくとも1つの腫瘍倍加期間について、50%以上腫瘍増殖阻害(TGI)と規定され、活性であった。14日間1日1回投薬した場合、これらの用量レベル全てにおいて、明らかな毒性は認められなかった。本研究において、25 mg/kgおよび50 mg/kgは、完全な腫瘍抑止をもたらした。前述の研究において、100 mg/kgをこのモデルに対して用いると、活性の増加が認められなかった。それ故に、25 mg/kgが、GTL-16腫瘍異種移植片に対する化合物1の、認められた最大有効量レベルである。本研究において、試験された最小用量レベルである6.25 mg/kgでもまた、50%TGI以上が得られたことから、これは本研究における最小有効量レベルを定める。また、U87ヒト神経膠芽腫モデル(Met活性化のHGFオートクリンメカニズムに基づくMet誘発腫瘍)に対しても、化合物1を試験した。図2に示すように、GTL-16腫瘍異種移植片に対して認められた活性と同様に、50および25 mg/kgの両方で完全な腫瘍抑止が認められた。
薬物代謝に関与する主要なヒトシトクロムP450(CYP)を阻害する化合物の能力を、組換えヒトCYPアイソフォームを用いてin vitroで評価した。バキュロウイルス-感染昆虫細胞から調製したcDNA-由来CYP酵素の阻害を、基質として3-シアノ-7-エトキシクマリン(CYP1A2, CYP2C19)、7-メトキシ-4-トリフルオロメチルクマリン(CYP2C9)または3-[2-(N,N-ジエチル-N-メチルアミノ)エチル]-7-メトキシ-4-メチルクマリン(CYP2D6)のいずれかを用いて測定した。CYP3A4阻害は、2つの基質で測定した: 7-ベンジルオキシ-4-トリフルオロメチルクマリン(BFC)およびレソルフィンベンジルエーテル(BzRes)。単一の濃度の各モデル基質(見かけのKm以下で試験したBFCを除いて、およそ見かけのKmで)、および約1/2対数単位により分けられた複数の濃度の試験化合物を、二つ組で試験した。モデル基質の代謝を、7-ヒドロキシ-3-シアノクマリン、3-[2-(N,N-ジエチルアミノ)エチル]-7-ヒドロキシ-4-メチルクマリン、7-ヒドロキシ-4-トリフルオロメチルクマリンまたはレソルフィンの産生によりアッセイし、蛍光検出により測定した。アッセイは、96ウェルマイクロタイタープレート中で、NADPH産生系の存在下において実施した。ポジティブコントロール試料をこれら試験に含んだ。全てのアッセイについて、該ポジティブコントロール値は従来の範囲内であった。該IC50値は、XLfit カーブ-フィッティングソフトウェアを用いて算出した。
8時間の経口曝露試験において、単一用量の50 mg/kgの該化合物を、70%PEG400/30%水溶液の状態で経口の経管栄養により、絶食成体雄性Balb/Cマウス(1化合物につきn=2または3)に投与した。これらの血清試料を、経口投与後0.5、1、4、8時間の時点で各マウスから採集した。最初の2試料は、眼窩後方からの採血により得て(〜100 μL/20-25 gマウス)、3つめの試料は心穿刺により得た。該血液試料は氷上で凝血させ、遠心した後、血清を採取した。分析前、血漿試料は〜20℃で保存した。該血漿試料は、HPLC結合-タンデム質量分析(LC/MS/MS)により、親化合物について分析された。
Claims (16)
- 該医薬的に許容される担体が微結晶セルロースおよびマンニトールまたはラクトースを含む、請求項2に記載の医薬組成物。
- さらに滑沢剤を含む、請求項2または3に記載の医薬組成物。
- さらに崩壊剤を含む、請求項2、3または4のうちのいずれか1つに記載の医薬組成物。
- 該癌がMet活性化に依存しており、該Met活性化が遺伝子増幅、活性化Met変異および/またはHGF刺激により制御されている、請求項6に記載の使用。
- 該癌が膀胱癌、乳癌、結腸直腸癌、胃癌、頭頸部癌、腎臓癌、肝臓癌、肺癌、卵巣癌、膵臓/胆嚢癌、前立腺癌、甲状腺癌、骨肉腫、横紋筋肉腫、MFH/線維肉腫、神経膠芽腫/星状細胞種、メラノーマまたは中皮腫である、請求項6または7に記載の使用。
- 膀胱癌、乳癌、結腸直腸癌、胃癌、頭頸部癌、腎臓癌、肝臓癌、肺癌、卵巣癌、膵臓/胆嚢癌、前立腺癌、甲状腺癌、骨肉腫、横紋筋肉腫、MFH/線維肉腫、神経膠芽腫/星状細胞種、メラノーマまたは中皮腫の治療に用いるための、請求項9に記載の化合物。
- 治療上有効な量の請求項1に記載の化合物もしくはその塩および少なくとも1つのさらなる抗癌剤を組み合わせて含む、癌の治療のための剤。
- 該さらなる抗癌剤が、ナイトロジェンマスタード、スルホン酸アルキル、ニトロソウレア、エチレンイミン誘導体およびトリアゼンを含むアルキル化剤; マトリックスメタロプロテアーゼ阻害剤を含む抗血管新生剤; アデノシンデアミナーゼ阻害剤、葉酸拮抗剤、プリンアナログ、およびピリミジンアナログを含む代謝拮抗剤; モノクローナル抗体、CTLA-4抗体、アントラサイクリンを含む抗生物質または抗体; アロマターゼ阻害剤; 細胞周期応答調節物質; 酵素; ファルネシル-タンパク質トランスフェラーゼ阻害剤; 合成アナログ、グルココルチコイド、SERMを含むエストロゲン/抗-エストロゲン、アンドロゲン/抗-アンドロゲン、プロゲスチン、プロゲステロン受容体アゴニスト、ならびに黄体ホルモン-放出[LHRH]アゴニストおよびアンタゴニストを含む、ホルモン剤、抗ホルモン剤およびステロイド; IGFR1阻害剤を含む、インスリン様増殖因子(IGF)/インスリン様増殖因子受容体(IGFR)系調節因子; インテグリン-シグナル伝達阻害剤; マルチ-キナーゼ阻害剤および/またはSrcキナーゼもしくはSrc/ablの阻害剤、サイクリン依存性キナーゼ[CDK]阻害剤、panHer、Her-1およびHer-2抗体、抗-VEGF抗体を含むVEGF阻害剤、EGFR阻害剤、マイトジェン活性化タンパク質[MAP]阻害剤、MEK阻害剤、オーロラキナーゼ阻害剤、PDGF阻害剤、ならびに他のチロシンキナーゼ阻害剤またはセリン/スレオニンキナーゼ阻害剤を含む、キナーゼ阻害剤; エクチナサイジンまたはそのアナログおよび誘導体を含む微小管-破壊剤; タキサン、並びに天然のエポチロンおよびその合成および半-合成アナログを含む、微小管-安定化剤; ビンカアルカロイドを含む、微小管-結合性、不安定化剤; トポイソメラーゼ阻害剤; プレニル-タンパク質トランスフェラーゼ阻害剤; 白金配位錯体; シグナル伝達阻害剤; ならびに、生物学的応答調節物質、増殖因子、および免疫調節剤を含む、抗癌剤および細胞毒性剤として用いられる他の薬剤からなる群から選択される、請求項11に記載の剤。
- 該癌がMet活性化に依存しており、該Met活性化が遺伝子増幅、活性化Met変異および/またはHGF刺激により制御されている、請求項11に記載の剤。
- 該癌が膀胱癌、乳癌、結腸直腸癌、胃癌、頭頸部癌、腎臓癌、肝臓癌、肺癌、卵巣癌、膵臓/胆嚢癌、前立腺癌、甲状腺癌、骨肉腫、横紋筋肉腫、MFH/線維肉腫、神経膠芽腫/星状細胞種、メラノーマまたは中皮腫である、請求項11に記載の剤。
- 請求項1に記載の化合物もしくはその塩;少なくとも1つのさらなる抗癌剤;および説明書を含む、癌の治療のためのキット。
- 該さらなる抗癌剤が、ナイトロジェンマスタード、スルホン酸アルキル、ニトロソウレア、エチレンイミン誘導体およびトリアゼンを含むアルキル化剤; マトリックスメタロプロテアーゼ阻害剤を含む抗血管新生剤; アデノシンデアミナーゼ阻害剤、葉酸拮抗剤、プリンアナログ、およびピリミジンアナログを含む代謝拮抗剤; モノクローナル抗体、CTLA-4抗体、アントラサイクリンを含む抗生物質または抗体; アロマターゼ阻害剤; 細胞周期応答調節物質; 酵素; ファルネシル-タンパク質トランスフェラーゼ阻害剤; 合成アナログ、グルココルチコイド、SERMを含むエストロゲン/抗-エストロゲン、アンドロゲン/抗-アンドロゲン、プロゲスチン、プロゲステロン受容体アゴニスト、ならびに黄体ホルモン-放出[LHRH]アゴニストおよびアンタゴニストを含む、ホルモン剤、抗ホルモン剤およびステロイド; IGFR1阻害剤を含む、インスリン様増殖因子(IGF)/インスリン様増殖因子受容体(IGFR)系調節因子; インテグリン-シグナル伝達阻害剤; マルチ-キナーゼ阻害剤および/またはSrcキナーゼもしくはSrc/ablの阻害剤、サイクリン依存性キナーゼ[CDK]阻害剤、panHer、Her-1およびHer-2抗体、抗-VEGF抗体を含むVEGF阻害剤、EGFR阻害剤、マイトジェン活性化タンパク質[MAP]阻害剤、MEK阻害剤、オーロラキナーゼ阻害剤、PDGF阻害剤、ならびに他のチロシンキナーゼ阻害剤またはセリン/スレオニンキナーゼ阻害剤を含む、キナーゼ阻害剤; エクチナサイジンまたはそのアナログおよび誘導体を含む微小管-破壊剤; タキサン、並びに天然のエポチロンおよびその合成および半-合成アナログを含む、微小管-安定化剤; ビンカアルカロイドを含む、微小管-結合性、不安定化剤; トポイソメラーゼ阻害剤; プレニル-タンパク質トランスフェラーゼ阻害剤; 白金配位錯体; シグナル伝達阻害剤; ならびに、生物学的応答調節物質、増殖因子、および免疫調節剤を含む、抗癌剤および細胞毒性剤として用いられる他の薬剤からなる群から選択される、請求項15に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85754006P | 2006-11-08 | 2006-11-08 | |
US60/857,540 | 2006-11-08 | ||
PCT/US2007/084047 WO2008058229A1 (en) | 2006-11-08 | 2007-11-08 | Pyridinone compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010509362A JP2010509362A (ja) | 2010-03-25 |
JP2010509362A5 JP2010509362A5 (ja) | 2010-12-24 |
JP5276005B2 true JP5276005B2 (ja) | 2013-08-28 |
Family
ID=39048786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009536476A Active JP5276005B2 (ja) | 2006-11-08 | 2007-11-08 | ピリジノン化合物 |
Country Status (21)
Country | Link |
---|---|
US (2) | US7851489B2 (ja) |
EP (1) | EP2089364B1 (ja) |
JP (1) | JP5276005B2 (ja) |
KR (1) | KR101390076B1 (ja) |
CN (1) | CN101535264B (ja) |
AR (1) | AR063628A1 (ja) |
AU (1) | AU2007317296B2 (ja) |
CA (1) | CA2669266C (ja) |
CL (1) | CL2007003226A1 (ja) |
DK (1) | DK2089364T3 (ja) |
ES (1) | ES2424851T3 (ja) |
HK (1) | HK1131608A1 (ja) |
HR (1) | HRP20130626T1 (ja) |
MX (1) | MX2009004699A (ja) |
NO (1) | NO342395B1 (ja) |
PE (1) | PE20081490A1 (ja) |
PL (1) | PL2089364T3 (ja) |
PT (1) | PT2089364E (ja) |
SI (1) | SI2089364T1 (ja) |
TW (1) | TWI409259B (ja) |
WO (1) | WO2008058229A1 (ja) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2531396T3 (es) | 2008-01-23 | 2015-03-13 | Bristol Myers Squibb Co | Proceso para preparar compuestos de piridinona |
JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン, インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
AU2011248441A1 (en) | 2010-04-29 | 2012-12-20 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
KR101897302B1 (ko) * | 2010-04-30 | 2018-09-11 | 브리스톨-마이어스 스큅 컴퍼니 | N-(4-(2-아미노-3-클로로피리딘-4-일옥시)-3-플루오로페닐)-4-에톡시-1-(4-플루오로페닐)-2-옥소-1,2-디히드로피리딘-3-카르복스아미드를 포함하는 제약 조성물 |
CN102241625B (zh) * | 2010-05-13 | 2014-10-29 | 中南大学 | 1-(取代芳基)-5-((取代芳胺基)甲基)吡啶-2(1h)酮化合物、制备方法及其用途 |
CN102070518B (zh) * | 2011-01-24 | 2012-05-02 | 江苏先声药物研究有限公司 | 取代吡啶及氮杂吲哚衍生物的合成 |
ES2923760T3 (es) | 2011-06-10 | 2022-09-30 | Merck Patent Gmbh | Composiciones y métodos para la producción de compuestos de pirimidina y piridina con actividad inhibidora de BTK |
RU2014125230A (ru) | 2011-11-22 | 2015-12-27 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность |
US8975282B2 (en) | 2012-07-28 | 2015-03-10 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
US8969388B1 (en) | 2012-07-28 | 2015-03-03 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
MX2018007774A (es) | 2015-12-22 | 2018-11-09 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
CN109890819B (zh) | 2016-06-20 | 2022-11-22 | 因赛特公司 | 作为免疫调节剂的杂环化合物 |
EP3484866B1 (en) * | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
RU2769693C2 (ru) * | 2016-12-19 | 2022-04-05 | Новартис Аг | Новые производные пиколиновой кислоты и их применение в качестве промежуточных соединений |
PE20191532A1 (es) | 2016-12-22 | 2019-10-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
WO2018136010A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
EP3589286B1 (en) | 2017-03-02 | 2022-08-03 | ASLAN Pharmaceuticals Pte Ltd | Dhodh inhibitor for treating haematological cancer |
CN108623568B (zh) * | 2017-03-21 | 2022-04-19 | 南京汇诚制药有限公司 | 9,10二氢菲类丙型肝炎病毒抑制剂的盐型及其制备 |
WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
WO2018222134A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
WO2019083457A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY |
WO2019083456A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS |
WO2019083455A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS |
WO2019083458A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA |
WO2019101178A1 (zh) | 2017-11-24 | 2019-05-31 | 南京明德新药研发股份有限公司 | 作为c-MET/AXL抑制剂的尿嘧啶类化合物 |
BR112020008663A2 (pt) | 2018-03-08 | 2020-10-06 | Wellmarker Bio Co., Ltd. | composto derivado de tienopiridina, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo |
MX2020012045A (es) | 2018-05-11 | 2021-03-29 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de ligando 1 de muerte programada (pd-l1). |
AU2019359036A1 (en) | 2018-10-09 | 2021-06-03 | Aslan Pharmaceuticals Pte Ltd | Malonate salt of varlitinib |
CA3116418A1 (en) * | 2018-10-19 | 2020-04-23 | The University Of British Columbia | Topoisomerase ii catalytic inhibitor compound therapeutics for cancer treatment, methods and uses |
WO2020150307A1 (en) * | 2019-01-15 | 2020-07-23 | The Translational Genomics Research Institute | Phosphonate conjugates and uses thereof |
JP2022543250A (ja) | 2019-08-02 | 2022-10-11 | ウェルマーカー・バイオ・カンパニー・リミテッド | オキソ-ピリジン縮合環誘導体、およびそれを含む医薬組成物 |
MX2022001671A (es) | 2019-08-09 | 2022-05-13 | Incyte Corp | Sales de un inhibidor de pd-1/pd-l1. |
EP3819300A4 (en) | 2019-09-06 | 2021-11-24 | Wellmarker Bio Co., Ltd. | THERAPEUTIC COMPOSITION BASED ON BIOMARKERS |
CN114829366A (zh) | 2019-11-11 | 2022-07-29 | 因赛特公司 | Pd-1/pd-l1抑制剂的盐及结晶形式 |
CN115003307A (zh) | 2020-02-06 | 2022-09-02 | 伟迈可生物有限公司 | 用于预防或治疗与kras突变相关的癌症的药物组合物 |
JP2023516381A (ja) | 2020-03-03 | 2023-04-19 | ウェルマーカー・バイオ・カンパニー・リミテッド | Kras変異および活性化ronが存在する癌の予防または治療のための医薬組成物 |
CN116390729A (zh) | 2020-05-18 | 2023-07-04 | 伟迈可生物有限公司 | 用于预防或治疗与ron突变相关的非小细胞肺癌的药物组合物及其使用方法 |
CN116685324A (zh) | 2020-05-18 | 2023-09-01 | 伟迈可生物有限公司 | 用于预防或治疗与ron突变相关的胰腺癌的药物组合物及其使用方法 |
EP4154892A4 (en) | 2020-05-18 | 2023-12-06 | Wellmarker Bio Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SMALL CELL LUNG CANCER ASSOCIATED WITH RON MUTANTS AND METHOD USING SAME |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
WO2022099071A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
WO2022169248A1 (ko) * | 2021-02-02 | 2022-08-11 | 주식회사 엘지화학 | 단백질 키나아제 억제제로서의 신규한 화합물 |
WO2022270881A1 (ko) * | 2021-06-22 | 2022-12-29 | 주식회사 엘지화학 | 단백질 키나아제 억제제로서의 신규한 화합물 |
US20230257364A1 (en) * | 2022-02-16 | 2023-08-17 | Cmg Pharmaceutical Co., Ltd. | Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof |
WO2024134517A1 (ko) * | 2022-12-23 | 2024-06-27 | 주식회사 엘지화학 | Ron 억제제로서 신규한 화합물 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0430885A3 (en) | 1989-12-01 | 1991-11-06 | Ciba-Geigy Ag | Anthelmintical compounds |
AU7340096A (en) | 1995-11-07 | 1997-05-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
EP1087937A1 (en) | 1998-06-17 | 2001-04-04 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
US6355660B1 (en) | 1999-07-20 | 2002-03-12 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
AU780698B2 (en) | 1999-07-20 | 2005-04-14 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
RU2002110461A (ru) | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Производные хиназолина и их применение в качестве фармацевтических веществ |
FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
SE0102384D0 (sv) | 2001-07-03 | 2001-07-03 | Pharmacia Ab | New compounds |
CA2468716A1 (en) | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
JP4829506B2 (ja) | 2004-02-17 | 2011-12-07 | 石原産業株式会社 | チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
ES2505090T3 (es) | 2004-05-07 | 2014-10-09 | Amgen Inc. | Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer |
US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
-
2007
- 2007-11-08 PL PL07844974T patent/PL2089364T3/pl unknown
- 2007-11-08 ES ES07844974T patent/ES2424851T3/es active Active
- 2007-11-08 WO PCT/US2007/084047 patent/WO2008058229A1/en active Application Filing
- 2007-11-08 MX MX2009004699A patent/MX2009004699A/es active IP Right Grant
- 2007-11-08 PE PE2007001538A patent/PE20081490A1/es active IP Right Grant
- 2007-11-08 DK DK07844974.1T patent/DK2089364T3/da active
- 2007-11-08 CA CA2669266A patent/CA2669266C/en active Active
- 2007-11-08 AR ARP070104987A patent/AR063628A1/es active Pending
- 2007-11-08 CN CN2007800414202A patent/CN101535264B/zh active Active
- 2007-11-08 AU AU2007317296A patent/AU2007317296B2/en active Active
- 2007-11-08 SI SI200731303T patent/SI2089364T1/sl unknown
- 2007-11-08 EP EP07844974.1A patent/EP2089364B1/en active Active
- 2007-11-08 CL CL200703226A patent/CL2007003226A1/es unknown
- 2007-11-08 KR KR1020097009449A patent/KR101390076B1/ko active IP Right Grant
- 2007-11-08 US US11/936,984 patent/US7851489B2/en active Active
- 2007-11-08 JP JP2009536476A patent/JP5276005B2/ja active Active
- 2007-11-08 PT PT78449741T patent/PT2089364E/pt unknown
- 2007-11-08 TW TW096142253A patent/TWI409259B/zh active
-
2009
- 2009-04-22 NO NO20091605A patent/NO342395B1/no unknown
- 2009-11-02 HK HK09110170.2A patent/HK1131608A1/xx unknown
-
2010
- 2010-11-08 US US12/941,419 patent/US8536200B2/en active Active
-
2013
- 2013-07-03 HR HRP20130626TT patent/HRP20130626T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CN101535264B (zh) | 2012-11-28 |
US20080114033A1 (en) | 2008-05-15 |
AR063628A1 (es) | 2009-02-04 |
PT2089364E (pt) | 2013-08-26 |
KR20090096423A (ko) | 2009-09-10 |
US7851489B2 (en) | 2010-12-14 |
HRP20130626T1 (en) | 2013-08-31 |
WO2008058229A1 (en) | 2008-05-15 |
PE20081490A1 (es) | 2008-10-30 |
HK1131608A1 (en) | 2010-01-29 |
SI2089364T1 (sl) | 2013-10-30 |
EP2089364B1 (en) | 2013-06-12 |
NO20091605L (no) | 2009-05-27 |
CA2669266C (en) | 2014-04-29 |
AU2007317296A1 (en) | 2008-05-15 |
CA2669266A1 (en) | 2008-05-15 |
KR101390076B1 (ko) | 2014-04-29 |
DK2089364T3 (da) | 2013-09-02 |
US20110052583A1 (en) | 2011-03-03 |
ES2424851T3 (es) | 2013-10-09 |
CN101535264A (zh) | 2009-09-16 |
PL2089364T3 (pl) | 2013-11-29 |
US8536200B2 (en) | 2013-09-17 |
MX2009004699A (es) | 2009-05-15 |
AU2007317296B2 (en) | 2012-07-05 |
JP2010509362A (ja) | 2010-03-25 |
TWI409259B (zh) | 2013-09-21 |
CL2007003226A1 (es) | 2008-02-08 |
EP2089364A1 (en) | 2009-08-19 |
NO342395B1 (no) | 2018-05-14 |
TW200829564A (en) | 2008-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5276005B2 (ja) | ピリジノン化合物 | |
US7880004B2 (en) | Met kinase inhibitors | |
JP5314050B2 (ja) | 4−ピリジノン化合物および癌についてのその使用 | |
EP1937682B1 (en) | Met kinase inhibitors | |
ES2218645T3 (es) | Derivados de benzamida, utiles como inductores de diferenciacion celular. | |
US7470693B2 (en) | Oxalamide derivatives as kinase inhibitors | |
US20070123534A1 (en) | Pyrrolotriazine kinase inhibitors | |
EP3083622B1 (en) | Maleimide derivatives as modulators of wnt pathway | |
WO2015187094A1 (en) | Phthalimide derivatives as modulators of wnt pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101105 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101105 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121218 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130507 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130516 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5276005 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |